Common Stock, par value $0.0001 per share
- Symbol
- DRMA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Dermata Therapeutics, Inc.
DRMANASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On August 5, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing the Company’s anticipated launch date for its first commercial product, Tome Foundational Treatment. The Company expects the Foundational Treatment to be available for sale, starting on August 25, 2026, with those on the waitlist getting early access to preorder.…
Company context
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata’s Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.
Current securities
Historical securities (1)
Registered securities in this filing
DERMATA THERAPEUTICS, INC. · 8-K · Filed 2026-08-05
Warrants, exercisable for one share of Common Stock
- Symbol
- DRMAW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Historical · closed Aug 17, 2026
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
August 5, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing the Company’s anticipated
launch date for its first commercial product, Tome Foundational Treatment. The Company expects the Foundational Treatment to be available
for sale, starting on August 25, 2026, with those on the waitlist getting early access to preorder. The Foundational Treatment
set includes four once-weekly treatments and will be available exclusively through www.tomeskincare.com for $178 (about $45/treatment).